Comparison of Transthoracic Esophagectomy with Definitive Chemoradiotherapy as Initial Treatment for Patients with Esophageal Squamous Cell Carcinoma Who Could Tolerate Transthoracic Esophagectomy

Satoru Matsuda, Yasuhiro Tsubosa, Masahiro Niihara, Hiroshi Sato, Katsushi Takebayashi, Keisuke Kawamorita, Keita Mori, Takahiro Tsushima, Tomoya Yokota, Hirofumi Ogawa, Yusuke Onozawa, Hirofumi Yasui, Hiroya Takeuchi, Yuukou Kitagawa

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: The oncological outcomes of transthoracic esophagectomy (TTE) and definitive chemoradiotherapy (dCRT) as initial treatment in patients with esophageal squamous cell carcinoma (ESCC) who could tolerate TTE remains unclear.

Methods: Consecutive patients histologically diagnosed with stage I/II/III ESCC (excluding cT4 or cN3) or stage IV ESCC due to supraclavicular lymph node metastasis were eligible for inclusion in this retrospective study. To select patients who could tolerate TTE, respiratory function, Eastern Cooperative Oncology Group performance status, and preoperative complications were considered. Patient characteristics, recurrence-free survival (RFS), 3- and 5-year overall survival (OS), pattern of recurrence, and treatments after initial treatment failure were investigated.

Results: Overall, 112 patients were included in the TTE group and 65 were included in the dCRT group. No significant differences were observed in patient characteristics and clinical stage between the TTE and dCRT groups (stage I/II/III/IV of 29/27/46/10 in the TTE group and 23/15/20/7 in the dCRT group). The R0 resection rate was 87 % in the TTE group, and complete response rate was 68 % in the dCRT group. In intention-to-treat analysis, there was no significant difference in RFS. In contrast, 3-year OS of non-stage IA patients was significantly longer in the TTE group than the dCRT group (TTE 66.9 %; dCRT 49.8 %; p = 0.023). In non-stage IA patients, after initial treatment failure significantly more patients could undergo local treatment (radiotherapy or surgery in the TTE group; surgery or endoscopic resection or photodynamic therapy in the dCRT group) in the TTE group than the dCRT group (TTE 74 %; dCRT 40 %; p = 0.003).

Conclusions: In locally advanced ESCC patients who could tolerate TTE, TTE extended 3-year OS, which might have been encouraged by utilizing local treatment after initial treatment failure.

Original languageEnglish
JournalAnnals of Surgical Oncology
DOIs
Publication statusAccepted/In press - 2015 Jan 7

Fingerprint

Esophagectomy
Chemoradiotherapy
Therapeutics
Treatment Failure
Survival
Esophageal Squamous Cell Carcinoma
Recurrence
Intention to Treat Analysis
Photochemotherapy

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Comparison of Transthoracic Esophagectomy with Definitive Chemoradiotherapy as Initial Treatment for Patients with Esophageal Squamous Cell Carcinoma Who Could Tolerate Transthoracic Esophagectomy. / Matsuda, Satoru; Tsubosa, Yasuhiro; Niihara, Masahiro; Sato, Hiroshi; Takebayashi, Katsushi; Kawamorita, Keisuke; Mori, Keita; Tsushima, Takahiro; Yokota, Tomoya; Ogawa, Hirofumi; Onozawa, Yusuke; Yasui, Hirofumi; Takeuchi, Hiroya; Kitagawa, Yuukou.

In: Annals of Surgical Oncology, 07.01.2015.

Research output: Contribution to journalArticle

Matsuda, Satoru ; Tsubosa, Yasuhiro ; Niihara, Masahiro ; Sato, Hiroshi ; Takebayashi, Katsushi ; Kawamorita, Keisuke ; Mori, Keita ; Tsushima, Takahiro ; Yokota, Tomoya ; Ogawa, Hirofumi ; Onozawa, Yusuke ; Yasui, Hirofumi ; Takeuchi, Hiroya ; Kitagawa, Yuukou. / Comparison of Transthoracic Esophagectomy with Definitive Chemoradiotherapy as Initial Treatment for Patients with Esophageal Squamous Cell Carcinoma Who Could Tolerate Transthoracic Esophagectomy. In: Annals of Surgical Oncology. 2015.
@article{1863059e631243128c7dd41cfb925ce8,
title = "Comparison of Transthoracic Esophagectomy with Definitive Chemoradiotherapy as Initial Treatment for Patients with Esophageal Squamous Cell Carcinoma Who Could Tolerate Transthoracic Esophagectomy",
abstract = "Background: The oncological outcomes of transthoracic esophagectomy (TTE) and definitive chemoradiotherapy (dCRT) as initial treatment in patients with esophageal squamous cell carcinoma (ESCC) who could tolerate TTE remains unclear.Methods: Consecutive patients histologically diagnosed with stage I/II/III ESCC (excluding cT4 or cN3) or stage IV ESCC due to supraclavicular lymph node metastasis were eligible for inclusion in this retrospective study. To select patients who could tolerate TTE, respiratory function, Eastern Cooperative Oncology Group performance status, and preoperative complications were considered. Patient characteristics, recurrence-free survival (RFS), 3- and 5-year overall survival (OS), pattern of recurrence, and treatments after initial treatment failure were investigated.Results: Overall, 112 patients were included in the TTE group and 65 were included in the dCRT group. No significant differences were observed in patient characteristics and clinical stage between the TTE and dCRT groups (stage I/II/III/IV of 29/27/46/10 in the TTE group and 23/15/20/7 in the dCRT group). The R0 resection rate was 87 {\%} in the TTE group, and complete response rate was 68 {\%} in the dCRT group. In intention-to-treat analysis, there was no significant difference in RFS. In contrast, 3-year OS of non-stage IA patients was significantly longer in the TTE group than the dCRT group (TTE 66.9 {\%}; dCRT 49.8 {\%}; p = 0.023). In non-stage IA patients, after initial treatment failure significantly more patients could undergo local treatment (radiotherapy or surgery in the TTE group; surgery or endoscopic resection or photodynamic therapy in the dCRT group) in the TTE group than the dCRT group (TTE 74 {\%}; dCRT 40 {\%}; p = 0.003).Conclusions: In locally advanced ESCC patients who could tolerate TTE, TTE extended 3-year OS, which might have been encouraged by utilizing local treatment after initial treatment failure.",
author = "Satoru Matsuda and Yasuhiro Tsubosa and Masahiro Niihara and Hiroshi Sato and Katsushi Takebayashi and Keisuke Kawamorita and Keita Mori and Takahiro Tsushima and Tomoya Yokota and Hirofumi Ogawa and Yusuke Onozawa and Hirofumi Yasui and Hiroya Takeuchi and Yuukou Kitagawa",
year = "2015",
month = "1",
day = "7",
doi = "10.1245/s10434-014-4337-7",
language = "English",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",

}

TY - JOUR

T1 - Comparison of Transthoracic Esophagectomy with Definitive Chemoradiotherapy as Initial Treatment for Patients with Esophageal Squamous Cell Carcinoma Who Could Tolerate Transthoracic Esophagectomy

AU - Matsuda, Satoru

AU - Tsubosa, Yasuhiro

AU - Niihara, Masahiro

AU - Sato, Hiroshi

AU - Takebayashi, Katsushi

AU - Kawamorita, Keisuke

AU - Mori, Keita

AU - Tsushima, Takahiro

AU - Yokota, Tomoya

AU - Ogawa, Hirofumi

AU - Onozawa, Yusuke

AU - Yasui, Hirofumi

AU - Takeuchi, Hiroya

AU - Kitagawa, Yuukou

PY - 2015/1/7

Y1 - 2015/1/7

N2 - Background: The oncological outcomes of transthoracic esophagectomy (TTE) and definitive chemoradiotherapy (dCRT) as initial treatment in patients with esophageal squamous cell carcinoma (ESCC) who could tolerate TTE remains unclear.Methods: Consecutive patients histologically diagnosed with stage I/II/III ESCC (excluding cT4 or cN3) or stage IV ESCC due to supraclavicular lymph node metastasis were eligible for inclusion in this retrospective study. To select patients who could tolerate TTE, respiratory function, Eastern Cooperative Oncology Group performance status, and preoperative complications were considered. Patient characteristics, recurrence-free survival (RFS), 3- and 5-year overall survival (OS), pattern of recurrence, and treatments after initial treatment failure were investigated.Results: Overall, 112 patients were included in the TTE group and 65 were included in the dCRT group. No significant differences were observed in patient characteristics and clinical stage between the TTE and dCRT groups (stage I/II/III/IV of 29/27/46/10 in the TTE group and 23/15/20/7 in the dCRT group). The R0 resection rate was 87 % in the TTE group, and complete response rate was 68 % in the dCRT group. In intention-to-treat analysis, there was no significant difference in RFS. In contrast, 3-year OS of non-stage IA patients was significantly longer in the TTE group than the dCRT group (TTE 66.9 %; dCRT 49.8 %; p = 0.023). In non-stage IA patients, after initial treatment failure significantly more patients could undergo local treatment (radiotherapy or surgery in the TTE group; surgery or endoscopic resection or photodynamic therapy in the dCRT group) in the TTE group than the dCRT group (TTE 74 %; dCRT 40 %; p = 0.003).Conclusions: In locally advanced ESCC patients who could tolerate TTE, TTE extended 3-year OS, which might have been encouraged by utilizing local treatment after initial treatment failure.

AB - Background: The oncological outcomes of transthoracic esophagectomy (TTE) and definitive chemoradiotherapy (dCRT) as initial treatment in patients with esophageal squamous cell carcinoma (ESCC) who could tolerate TTE remains unclear.Methods: Consecutive patients histologically diagnosed with stage I/II/III ESCC (excluding cT4 or cN3) or stage IV ESCC due to supraclavicular lymph node metastasis were eligible for inclusion in this retrospective study. To select patients who could tolerate TTE, respiratory function, Eastern Cooperative Oncology Group performance status, and preoperative complications were considered. Patient characteristics, recurrence-free survival (RFS), 3- and 5-year overall survival (OS), pattern of recurrence, and treatments after initial treatment failure were investigated.Results: Overall, 112 patients were included in the TTE group and 65 were included in the dCRT group. No significant differences were observed in patient characteristics and clinical stage between the TTE and dCRT groups (stage I/II/III/IV of 29/27/46/10 in the TTE group and 23/15/20/7 in the dCRT group). The R0 resection rate was 87 % in the TTE group, and complete response rate was 68 % in the dCRT group. In intention-to-treat analysis, there was no significant difference in RFS. In contrast, 3-year OS of non-stage IA patients was significantly longer in the TTE group than the dCRT group (TTE 66.9 %; dCRT 49.8 %; p = 0.023). In non-stage IA patients, after initial treatment failure significantly more patients could undergo local treatment (radiotherapy or surgery in the TTE group; surgery or endoscopic resection or photodynamic therapy in the dCRT group) in the TTE group than the dCRT group (TTE 74 %; dCRT 40 %; p = 0.003).Conclusions: In locally advanced ESCC patients who could tolerate TTE, TTE extended 3-year OS, which might have been encouraged by utilizing local treatment after initial treatment failure.

UR - http://www.scopus.com/inward/record.url?scp=84920861427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920861427&partnerID=8YFLogxK

U2 - 10.1245/s10434-014-4337-7

DO - 10.1245/s10434-014-4337-7

M3 - Article

C2 - 25564176

AN - SCOPUS:84939998090

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

ER -